GlycA

Elevated levels of GlycA typically signify an increased presence of glycosylated acute-phase proteins in the bloodstream. These acute-phase proteins are released from the liver in response to inflammation or infection, and their glycosylation status can change during such immune responses. Therefore, elevated GlycA levels are considered indicative of systemic inflammation within the body.

Elevated GlycA levels may suggest the presence of underlying inflammation-related conditions, such as infections, autoimmune disorders, cardiovascular diseases, or chronic inflammatory conditions like rheumatoid arthritis.

Monitoring GlycA levels can be helpful in assessing the extent and persistence of inflammation, disease activity, and response to treatment.

It's important to note that while elevated GlycA levels can indicate the presence of inflammation, they do not provide a specific diagnosis of the underlying cause. Further clinical evaluation, including a detailed medical history, physical examination, and possibly additional tests, would be needed to identify the specific condition or disease associated with the elevated GlycA levels and to determine the appropriate treatment and management plan.

The GlycA test assesses a specific NMR signal, distinct from lipoprotein particle analysis, and is regarded as a potential marker of systemic inflammation, offering clinical utility comparable to high sensitivity C-reactive protein (hsCRP), fibrinogen, and other inflammation biomarkers. This NMR signal, termed "GlycA," originates from N-acetylglucosamine moieties on circulating glycoproteins' carbohydrate portions.